2248792
Last Update Posted: 2014-09-25
Recruiting status is unknown
All Genders accepted | 18 Years-65 Years |
50 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.
Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.
Eligibility
Relevant conditions:
Severe Plaque Type Psoriasis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Data sourced from ClinicalTrials.gov